Loading clinical trials...
Loading clinical trials...
Maintenance Treatment With Oral Azacitidine for Patients With de Novo AML Including t-AML and AML-MRC in First Remission After CPX-351
Conditions
Interventions
No intervention
Locations
1
France
CHU de Nice
Nice, France
Start Date
January 1, 2020
Primary Completion Date
January 1, 2025
Completion Date
January 1, 2025
Last Updated
April 5, 2024
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT04628026
NCT06994676
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions